Fasting hyperglucagonemia can be detrimental to glucose metabolism in patients with type 2 diabetes (T2D) and may contribute to metabolic disturbances in obese and/or prediabetic subjects. However, the mechanisms underlying fasting hyperglucagonemia remain elusive.
Methods:
We evaluated the interrelationship between fasting hyperglucagonemia and demographic and biochemical parameters in 106 patients with T2D (31% female, age: 57 ± 9 years [mean ± standard deviation; body mass index (BMI): 30.1 ± 4.4 kg/m2; fasting plasma glucose (FPG): 9.61 ± 2.39 mM; hemoglobin A1c (HbA1c): 57.1 ± 13.1 mmol/mol] and 163 nondiabetic control subjects (29% female; age: 45 ± 17 years; BMI: 25.8 ± 4.1 kg/m2; FPG: 5.2 ± 0.4 mM; and HbA1c: 35.4 ± 3.8 mmol/mol). Multiple linear regression analysis was applied using a stepwise approach with fasting plasma glucagon as dependent parameter and BMI, waist-to-hip ratio (WHR), blood pressure, hemoglobin A1c, FPG, and insulin concentrations as independent parameters.
Results:
Fasting plasma glucagon concentrations were significantly higher among patients with T2D (13.5 ± 6.3 vs. 8.5 ± 3.8 mM, P < 0.001) together with HbA1c (P < 0.001), FPG (P < 0.001), and insulin (84.9 ± 56.4 vs. 57.7 ± 35.3 mM, P < 0.001). When adjusted for T2D, HbA1c and insulin were significantly positive determinants for fasting plasma glucagon concentrations. Furthermore, WHR comprised a significant positive determinant.
Conclusions:
We confirm that fasting plasma glucagon concentrations are abnormally high in patients with T2D, and show that fasting plasma glucagon concentrations are influenced by WHR (in addition to glycemic control and fasting plasma insulin concentrations), which may point to visceral fat deposition as an important determinant of increased fasting plasma glucagon concentrations.
Get full access to this article
View all access options for this article.
References
1.
CampbellJE, DruckerDJ. Islet α cells and glucagon—Critical regulators of energy homeostasis. Nat Rev Endocrinol, 2015; 11:329–338.
2.
AnderssonP-O, FarneboL-O, FredholmBB, et al.Metabolic and hormonal adjustments during hemorrhage in cats after interference with the sympatho-adrenal system. Acta Physiol Scand, 1982; 114:111–119.
3.
VrangN, LarsenPJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Prog Neurobiol, 2010; 92:442–462.
4.
SandovalDA, D'AlessioDA. Physiology of proglucagon peptides: Role of glucagon and GLP-1 in health and disease. Physiol Rev, 2015; 95:513–548.
5.
DunningBE, GerichJE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev, 2007; 28:253–283.
6.
GromadaJ, FranklinI, WollheimCB. α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev, 2007; 28:84–116.
7.
UngerRH, OrciL. Glucagon and the A cell: Physiology and pathophysiology (first two parts). N Engl J Med, 1981; 304:1518–1524.
8.
SuppliMP, LundA, BaggerJI, et al.Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. Med Hypotheses, 2016; 86:100–103.
9.
SonneDP, RehfeldJF, HolstJJ, et al.Postprandial gallbladder emptying in patients with type 2 diabetes: Potential implications for bile-induced secretion of glucagon-like peptide 1. Eur J Endocrinol, 2014; 171:407–419.
10.
ShahP, VellaA, AndanaB, et al.Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2000; 85:4053–4059.
11.
LundA, BaggerJI, ChristensenM, et al.Glucagon and type 2 diabetes: The return of the alpha cell. Curr Diab Rep, 2014; 14:555.
12.
UngerRH, CherringtonAD. Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest, 2012; 122:4–12.
13.
KazdaCM, GarhyanP, KellyRP, et al.A randomized, double-blind, placebo-controlled phase 2 study of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes. Diabetes Care, 2015; 41. DOI: 10.2337/dc15-1643.
14.
KnopFK, VilsbøllT, LarsenS, et al.No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care, 2003; 26:2581–2587.
15.
KnopFK, VilsbøllT, LarsenS, et al.Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab, 2007; 292:E324–E330.
16.
KnopFK, VilsbøllT, HøjbergPV, et al.Reduced incretin effect in type 2 diabetes cause or consequence of the diabetic state?. Diabetes, 2007; 56:1951–1959.
17.
KnopFK, VilsbøllT, MadsbadS, et al.Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia, 2007; 50:797–805.
18.
AaboeK, KnopFK, VilsbøllT, et al.KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab, 2009; 94:603–608.
19.
HareKJ, KnopFK, MeenaA, et al.Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab, 2009; 94:4679–4687.
20.
HareKJ, VilsbøllT, HolstJJ, et al.Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. Am J Physiol Endocrinol Metab, 2010; 298:E832–E837.
21.
AaboeK, KnopFK, VilsbøllT, et al.Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2010; 12:323–333.
22.
KnopFK, VilsbøllT, LarsenS, et al.Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. Regul Pept, 2010; 164:144–150.
23.
HansenKB, VilsbøllT, BaggerJI, et al.Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab, 2011; 96:447–453.
24.
BaggerJI, KnopFK, LundA, et al.Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab, 2011; 96:737–745.
25.
LundA, VilsbøllT, BaggerJI, et al.The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab, 2011; 300:E1038–E1046.
26.
ChristensenM, VedtofteL, HolstJJ, et al.Glucose-dependent insulinotropic polypeptide. Diabetes, 2011; 60:3103–3109.
27.
KnopFK, AaboeK, VilsbøllT, et al.Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab, 2012; 14:500–510.
28.
HansenKB, VilsbøllT, BaggerJI, et al.Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. J Clin Endocrinol Metab, 2012; 97:1363–1370.
29.
BaggerJ, HolstJ, VilsbøllT, et al.Glucagon and the gut hormones GLP-1 and oxyntomodulin increase resting energy expenditure in man. Regul Pept, 2012; 177:S15–S16.
30.
BondeL, VilsbøllT, NielsenT, et al.Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus. Diabetes Obes Metab, 2013; 15:713–720.
31.
ChristensenM, CalannaS, HolstJJ, et al.Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab, 2014; 99:E418–E426.
32.
RheeNA, ØstoftSH, HolstJJ, et al.The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. Eur J Endocrinol, 2014; 171:353–362.
33.
GyldenløveM, StorgaardH, HolstJJ, et al.Patients with psoriasis are insulin resistant. J Am Acad Dermatol, 2015; 72:599–605.
34.
GyldenløveM, VilsbøllT, ZachariaeC, et al.Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. J Intern Med, 2015; 278:660–670.
35.
HansenM, SheltemaMJ, SonneDP, et al.Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab, 2016; 18:571–580.
36.
LundA, BaggerJI, AlbrechtsenNJW, et al.Evidence of extrapancreatic glucagon secretion in man. Diabetes, 2016; 65:585–597.
37.
LundA, BaggerJI, ChristensenM, et al.Higher endogenous glucose production during OGTT vs isoglycemic intravenous glucose infusion. J Clin Endocrinol Metab, 2016; 101:4377–4384.
38.
WHO | Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Accessed at http://www.who.int.ep.fjernadgang.kb.dk/diabetes/publications/diagnosis_diabetes2006/en on January 17, 2017.
39.
ØrskovC, JeppesenJ, MadsbadS, et al.Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest, 1991; 87:415–423.
40.
BakMJ, AlbrechtsenNJW, PedersenJ, et al.Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol, 2014; 170:529–538.
41.
UngerRH, OrciL. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet Lond Engl, 1975; 1:14–16.
42.
ReavenGM, ChenY-DI, GolayA, et al.Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1987; 64:106–110.
43.
GysinB, JohnsonDG, TrivediD, et al.Synthesis of two glucagon antagonists: Receptor binding, adenylate cyclase, and effects on blood plasma glucose levels. J Med Chem, 1987; 30:1409–1415.
44.
Van TineBA, AzizehBY, TrivediD, et al.Low level cyclic adenosine 3′,5′-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology, 1996; 137:3316–3322.
45.
ParkerJC, McPhersonRK, AndrewsKM, et al.Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes, 2000; 49:2079–2086.
46.
MadsenP, LingA, PleweM, et al.Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem, 2002; 45:5755–5775.
ShenD-M, ZhangF, BradyEJ, et al.Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem Lett, 2005; 15:4564–4569.
49.
LadouceurGH, CookJH, DohertyEM, et al.Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. Bioorg Med Chem Lett, 2002; 12:461–464.
50.
PotteratO, WagnerK, GemmeckerG, et al.BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp. J Nat Prod, 2004; 67:1528–1531.
51.
KnappeTA, LinneU, XieX, et al.The glucagon receptor antagonist BI-32169 constitutes a new class of lasso peptides. FEBS Lett, 2010; 584:785–789.
52.
MadsenP, KodraJT, BehrensC, et al.Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. J Med Chem, 2009; 52:2989–3000.
53.
MadsenP, KnudsenLB, WibergFC, et al.Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem, 1998; 41:5150–5157.
54.
MeierJJ, DeaconCF, SchmidtWE, et al.Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia, 2007; 50:806–813.
55.
FærchK, PilgaardK, KnopFK, et al.Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes Obes Metab, 2013; 15:91–95.
56.
MitrakouA, KelleyD, MokanM, et al.Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med, 1992; 326:22–29.
57.
JunkerAE, GluudLL, van HallG, et al.Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. J Hepatol, 2016; 64:908–915.
58.
CharbonneauA, CouturierK, GauthierM-S, et al.Evidence of hepatic glucagon resistance associated with hepatic steatosis: Reversal effect of training. Int J Sports Med, 2005; 26:432–441.
59.
RaddatzD, RossbachC, BuchwaldA, et al.Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS). Exp Clin Endocrinol Diabetes, 2005; 113:268–274.
60.
FerranniniE, MuscelliE, NataliA, et al.Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia, 2007; 50:2342–2347.
61.
AlbrechtsenNJW, KuhreRE, PedersenJ, et al.The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med, 2016; 10:1141–1151.
62.
Knop FKEJ. E PRIZE. 2018: A gut feeling about glucagon. Eur J Endocrinol, 2018Jun; 178:R267–R280.
DeanED, LiM, PrasadN, et al.Interrupted glucagon signaling reveals hepatic α cell axis and role for L-glutamine in α cell proliferation. Cell Metab, 2017; 25:1362–1373.e5.
65.
HolstJJ, AlbrechtsenNJW, PedersenJ, et al.Glucagon and amino acids are linked in a mutual feedback cycle: The liver-α-cell axis. Diabetes, 2017; 66:235–240.
66.
JakobsenMU, BerentzenT, SørensenTIA, et al.Abdominal obesity and fatty liver. Epidemiol Rev, 2007; 29:77–87.
67.
ChanDC, WattsGF, NgTWK, et al.Measurement of liver fat by magnetic resonance imaging: Relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab, 2006; 8:698–702.
68.
ZhengR-D, ChenZ-R, ChenJ-N, et al.Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease. Gastroenterol Res Pract, 2012; 2012:362147.
69.
AshwellM, ColeTJ, DixonAK. Obesity: New insight into the anthropometric classification of fat distribution shown by computed tomography. Br Med J Clin Res Ed, 1985; 290:1692–1694.
70.
SeidellJC, BjörntorpP, SjöströmL, et al.Regional distribution of muscle and fat mass in men—New insight into the risk of abdominal obesity using computed tomography. Int J Obes, 1989; 13:289–303.
71.
HeibelSK, LopezGY, PanglaoM, et al.Transcriptional regulation of N-acetylglutamate synthase. PLoS One, 2012; 7:e29527.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
